Edition: Global Global Select Region
Email: Passwd: or sign up free
One News Page
One News Page > Business > RegMed sector, salvaging a bad year; Cell Therapy might be poised for a comeback
Open news article

RegMed sector, salvaging a bad year; Cell Therapy might be poised for a comeback

Proactive Investors
Thursday, 27 December 2012

*The 6 W’s: Who, what, where, when, why and what of it*

*                      ** *

*RegMed stocks were either flat and little changed on Wednesday as many just … took the day – off. There’s just no certainty and people don’t know where to step. We’re in a quandary here – the market doesn’t CAtch on … there’s not a lot of volume and you have a lot of traders with question marks in their heads right now.*


*Following up … this morning’s comments … 2013 will be guided … by surprises in that … Cell Therapy might be poised for a comeback …http://www.scimitarequity.com/blog/2012/12/26/regmed-sector-slightly-higher-open-expected . **CArdiology is a popular field for cell-therapy research. The only large player with an in-house cell-therapy program, Baxter International (BAX), is conducting a P3 trial of an autologous therapy for chronic myoCArdial ischemia, or insufficient blood flow to the heart, the No. 1 CAuse of death in the U.S. Osiris Therapeutics (OSIR) is even further along with its allogeneic product Prochymal, approved in CAnada and New Zealand to treat transplant resistance, and awaiting FDA approval. It’s also being evaluated as a way to rebuild the heart after an attack, which would be a much larger market. In a sign of the industry’s struggles, however, OSIR lost its heavyweight partner Genzyme last year after the latter was acquired by Sanofi (SNY), which chose to end the relationship. Mesoblast faced a similar prospect when Teva acquired its partner Cephalon…*

*Big Pharma still doesn’t get cell therapy … Brozak laments … But he says eventually it will have to. “The pill-a-day model is dead and buried,” he said. “Any large pharma that doesn’t understand that will go the way of the buggy whip.” Read More At IBD:http://news.investors.com/technology/122112-638001-cell-therapy-could-shake-off-provenge-blues.htm#ixzz2GAfYvAu2*

* *

*Who is also up – Advanced Cell Technology (OTC: ACTC+$0.0001), Bioheart (PINK: BHRT +$0.001), BioMimetic (BMTI +$0.06), Dendreon (DNDN +$0.03), Fibrocell (OTC: FCSC +$0.003), International  Stem Cell (OTC: ISCO+$0.01), NeoStem (NYSE MKT: NBS +$0.003), Proteonomix (OTC: PROT +$0.009) and ReNeuron (RENE.L +$0.18). *

*Mid-Day: The NASDAQ is DOWN -23.61 (-0.78%) to 2,988.99 while the Dow is DOWN -50.89 (-0.39%) to 13,088.19.*

*Measuring the day – NEGATIVE – 9 green (ups) following 17 red (downs) and 6-7 fluctuating black (flats) … The CBOE Volatility Index traded above 19.*

* *

*My Model Portfolio and IndiCAtors:*
· *Aastrom (ASTM) is UP … +$0.01 or +0.66% at $1.35 in a slightly expanding mid-day range of $1.31 – $1.35 with a lower 71 K volume … compared to 12/24’s closing range of $1.34 – $1.37 with larger volume of 74.2 K. I have maintained a “BUY” in this market and at this pricing beCAuse of the late stage trial status.***
· *BioLife Solutions (OTC: BLFS) is FLAT … to $0.29 … with a trading range of $0.29 – $0.29 … with only thin 6 K share volume compared to 12/24’s closing range of $0.29 to $0.29 and 0 share volume.  I continue to reiterate this as a “BUY” on downdraft … still sticking to BLFS being under-valued –with a $0.50 target! In a couple of CAlls … those same traders are coming back as they CAn NOT keep this equity down!!*
· *Cytori (CYTX) is DOWN … -$0.02 or -0.76% to $2.64 … after an offering at $2.85 for $18.5 M with an expanding  trading range of $2.58 – $2.70 and volume of 182 K shares from 12/24’s closing wide range of $2.62 – $2.75 with 284.7 K  volume … I project… a “HOLD” for … until the offering settles … now a “show me” stock! An interesting prophecy … the over-allotment won’t be fulfilled!*
· *Cytomedix (OTC: CMXI) is DOWN … -$0.026 or -3.53% at $0.71 with an expanding and  tighter trading range of $0.72 to $0.79 with moderate volume of 75 K shares from 12/24’s closing range of $0.73 to $0.80 and still low 51 K share volume. CMXI is undervalued and ranked a “BUY” as most recently stated it was worth $1.25 … at a minimum.** *
· *NeoStem (NYSE MKT: NBS) is UP  … +$0.003 or +0.46% at $0.61 … with a tighter day’s range of $0.61 -$0.62 … with low 252 K volume so far from 12/24’s closing range of $0.60 – $0.62 with moderate 222.1 K share volume. NBS continue a “BUY” as I have been iterating for a while! But, day traders, retail and individual investors are slowing the year down!*

* *

*Worth mentioning:*
· *NEURALSTEM (NYSE MKT: CUR), KARL JOHE sells 12,800 shares at $1.16*
· *LLOYD H DEAN, Director, of Cytori (CYTX) BUYS 25,000 ON 12/19/12 OF CYTX*
· *DAVID M RICKEY, Director of Cytori (CYTX)  BUYS  32,000 ON 12/19/12 OF CYTX*
· *MARC H HEDRICK, President of Cytori (CYTX) BUYS 10,000 ON 12/19/12 OF CYTX*
· *Tengion’s (OTC QB: TNGN), Scott D. Flora, President  & CEO at OmniGuide, has resigned from TNGN’s Board of Directors, effective 12/19/12;*
· * Richard J Berman, Director, NEOSTEM, (NYSE MKT: NBS) has sold 149,306 SHARES OF NBS*
· *MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) presented at the 2012 AmeriCAn Society for Cell Biology® (ASCB®) Annual Meeting in San Francisco, CA, on Tuesday, December 18. Simona Bot, M.D. presented precliniCAl research results in an abstract titled“Short Synthetic Double Stranded RNA with Dual Activity – Oncolytic and Immune Modulatory – for Hepatocellular CArcinoma.”This research was supported by MultiCell via a sponsored research grant with the laboratory of Anand Ghanekar , M.D., Ph.D. at University Health Network, Toronto General Hospital Research Institute, Ontario, CAnada. The scientific results presented by Dr. Bot added key information regarding the CApability of MCT-485 to elicit highly pro-inflammatory cytokine by human monocytes, and death of human liver CAncer cells, mostly through a mechanism distinct from apoptosis. Together with the data previously presented at the Association of CAncer Immunotherapy (CIMT annual meeting, May 2012, Mainz, Germany) describing the direct anti-tumor cell effect of MCT-485 on multiple human liver CAncer cell lines in vitro, the novel scientific evidence supports the model that this synthetic dsRNA molecule could mediate a two-pronged effect within the tumor environment: destruction of the tumor cells and activation of the stromal monocytes. The latter could amplify the immune system’s CApability to fight off tumor over a longer timeframe.Altogether, these data sets, generated for the first time with MCT-485 manufactured using a state of the art process, as presented at CIMT and ASCB® 2012, support further studies exploring the precliniCAl safety, effectiveness and cliniCAl utility of this CAndidate as a novel therapeutic agent for hepatocellular CArcinoma.*
Share on FacebookShare on Twitter Comment

You Might Like

Other recent news in Business

Wall Street up on APPLE, Caterpillar; Ukraine weighsThe Wall Street Journal: MICROSOFT profits slip; sales rise on software, Surface
Microsoft (MSFT) Beats Wall Street's Estimates For Fiscal Q3 Although SALES FallApple, GOOGLE, Adobe and Intuit settle Silicon Valley poaching case
Apple lifts Nasdaq; UKRAINE drags on broader marketAMAZON Shares Rise As Sales Growth Remains Strong
Heineken first-quarter sales beat analyst estimatesSTARBUCKS eyes soda and lunch as US sales climb
Ukrainian Troops Make Push Into East Ukraine City Held By Trained Pro-RUSSIA GunmanWill your city get super-fast INTERNET from Google?



comments powered by Disqus

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2014 One News Page Ltd. All Rights Reserved.  |  About us  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
One News Page - Top Headlines RSS Feed RSS  |  News for my Website  |  Free news search widget  |  Advertise  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |  One News Page on Facebook LIKE us on Facebook  One News Page on Twitter FOLLOW us on Twitter  One News Page on Google+ FIND us on Google+

Bullet: One News Page official news app for iPhone Bullet: Our news app for iPhone